STILL’S DISEASE TREATMENT MARKET ANALYSIS (2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
STILLS DISEASE TREATMENT MARKET ANALYSIS
(2020-2027)

• Stills Disease Treatment Market, by Treatment
  (Pain Management, Corticosteroids, Tocilizumab,
  Canakinumab, Anakinra, and Others), by Route of
  Administration (Injectable and Oral), by
  Distribution Channel (Retail Pharmacies, Hospital
  Pharmacies, and Online Pharmacies), and by Region
  (North America, Latin America, Europe, Asia
  Pacific, Middle East, and Africa) - Size, Share,
  Outlook, and Opportunity Analysis, 2020 - 2027

3

• Stills disease is a rare rheumatic condition.
  This condition is characterized by biological and
  clinical symptoms such as high spiking fever,
  joint swelling, muscle pain, sore throat,
  increased number of white cells (leukocytes,
  especially neutrophils), and biological
  hepatitis. Treatment for stills disease can be
  classified into 2 categories, namely symptomatic
  treatments and effective therapies. Symptomatic
  treatments can be initiated immediately, even
  when the diagnosis has not been established
  whereas, effective therapies are designed to
  treat the condition more efficiently to eradicate
  the symptoms of the disease.

4

• According to a study published in The American
  Journal of Medicine, the treatment of stills
  disease has been largely derived from
  retrospective data and case reports. While mild
  cases can be treated with NSAIDs (Nonsteroidal
  Anti-inflammatory Drugs), more than 80 of
  stills disease patients need the use of
  corticosteroids and do not achieve remission.
  There is no such known risk factor that develops
  the Stills disease, however, it is assumed that
  it is caused due to over activation of IL-1
  (Interleukin-1) in the body.
• The rising demand for specific new treatments and
  the emergence of drugs for stills disease are
  expected to drive the stills disease treatment
  market growth during the forecast period. For
  instance, as per the U.S. Food and Drug
  Administration (FDA), Canakinumab (Ilaris) can be
  indicated to all patients older than 2 years with
  Still's disease.

5
Stills Disease Treatment Market - Impact of
Coronavirus (Covid-19) Pandemic

• Stills disease treatment market is hugely
  affected due to the outbreak of COVID-19, as it
  is becoming difficult for researchers to conduct
  researches during this pandemic situation. People
  with rheumatic diseases such as Still's disease
  are more prone to getting infected with the
  coronavirus. Thus, majority of the vendors are
  concentrating on developing strategies to help
  patients with stills disease to remain agile
  during the global disruptions due to COVID-19
  pandemic. In addition, many government bodies
  across the globe are taking decisions such as new
  regulations to deal with the current crisis.

6

• The all-inclusive version of the report will
  include the impact of COVID-19 and the probable
  changes in the future outlook of the industry, by
  taking into account the technological, social,
  political, and economical parameters.
• The stills disease treatment market is estimated
  to be valued at US 1,539.4 million in 2020 and
  is expected to rise at a CAGR of 4.49 during the
  forecast period (2020-2027).

7
Figure 1. Stills Disease Treatment Market Share
() Analysis, By Route of Administration, 2020
8

• An increase in the number of mergers
  acquisitions and drug launches is expected to
  propel growth of the stills disease treatment
  market
• Key players in the market are involved in mergers
  acquisitions to develop advanced drugs and
  treatment, and launch them in the stills disease
  treatment market. The drug launches in the
  industry is estimated to significantly boost the
  market growth and create lucrative growth
  opportunities in the overall market during the
  forecast period.
• For instance, in July 2018, SOBI launched a
  third-line treatment, Kineret drug for the
  treatment of adult-onset still's disease (AOSD).
  This new therapy is indicated when the patient
  does not respond to Disease-modifying
  antirheumatic drugs (DMARDs)  and
  corticosteroids, and fail to respond to
  methotrexate. The drug is currently available in
  the U.K. for Cryopyrin-associated periodic
  syndromes (CAPS) and rheumatoid arthritis (RA).

9

• Furthermore, companies are adopting several
  strategies such as license agreements and
  partnerships to hold a strong position in the
  global industry. For instance, in July 2019, Aevi
  Genomic Medicine entered into a license agreement
  with AstraZeneca for phase II trials of MEDI2338,
  which is a fully human mAb (monoclonal antibody)
  that targets IL-18 (interleukin 18). The company
  has planned to initially develop MEDI2338 for
  AOSD (adult-onset Still's disease), which is a
  rare and orphan rheumatological disease with
  presently no approved biologic therapies in the
  U.S.

10
Stills Disease Treatment Market - Restraints

• Unavailability of specific therapeutics for
  stills disease condition is considered to be one
  of the potential restraints affecting the market
  growth. For instance, the treatment for stills
  disease is directed towards the use of
  anti-inflammatory drugs such as aspirin and other
  nonsteroidal drugs (NSAIDs). In some cases,
  cortisone medications such as prednisone are used
  to treat the condition. Other factors such as
  increasing number of generic therapeutics,
  product recalls, and patent expiration of
  licenses various drugs are likely to hamper the
  market growth.

11
(No Transcript)
12
Stills Disease Treatment Market Regional
Analysis

• Europe region accounted for the largest share in
  the stills disease treatment market in 2019,
  owing to the increasing focus of key players on
  research development and European Commission
  (EC) approvals in the market. For instance, in
  April 2018, Swedish Orphan Biovitrum AB announced
  that Kineret (anakinra) is approved by the EC for
  the treatment of stills disease. Kineret is
  indicated for adults, children, adolescents, and
  infants aged 8 months and above with at least
  10kg bodyweight for the treatment of Stills
  disease. This also includes AOSD and SJIA with
  active systemic features of moderate to high
  disease activity.

13

• The U.S. market followed the same. In June 2020,
  the U.S. FDA approved Switzerland-based
  Novartiss Ilaris injection for the treatment of
  active stills disease. This approval also
  includes treatment for Adult-Onset Stills
  Disease (AOSD). The Ilaris injection was formerly
  approved for SJIA (Systemic Juvenile Idiopathic
  Arthritis) in patients aged 2 years and above.
• The Asia Pacific region is witnessing a promising
  growth in the global stills disease treatment
  market, owing to initiatives taken by key players
  and approvals for the treatment of adult stills
  disease. For instance, in May 2019, Chugai
  Pharmaceutical Co., Ltd., a subsidiary of F.
  Hoffmann-La Roche Ltd.  received expanded
  approval from the MHLA (Ministry of Health Labor
  and Welfare) in Japan for Actemra (tocilizumab)
  for the treatment of adult Stills disease.

14

• Figure 2. Stills Disease Treatment Market Value
  (US Mn) Y-o-Y Growth (), 2017-2027

15
Global Stills Disease Treatment Market -
Competitive Landscape

• Key players operating in the Stills disease
  treatment market include AB2 Bio Ltd., F.
  Hoffmann-La Roche Ltd, Novartis AG, Swedish
  Orphan Biovitrum AB, Jubilant Life Sciences Ltd,
  Vintage Labs, Hikma Pharmaceuticals PLC, Teva
  Pharmaceutical Industries Ltd, Mylan N.V.,
  Horizon Therapeutics plc, Sun Pharmaceutical
  Industries Ltd, Zydus Cadila, Amneal
  Pharmaceuticals LLC, Dr Reddy's Laboratories
  Ltd., and Fresenius Kabi AG.

16

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  market-insight/stills-disease-treatment-market-402
  3

17
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

18
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

19

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/